These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35139366)

  • 1. The effect of favipiravir versus hydroxychloroquine on clinical and laboratory findings in COVID-19 in healthcare workers.
    Turan DB; Menteş M; Özel Y; Şerefhanoğlu K; Aydoğan B; İbil N; Güneşdoğdu F; Orucova HM; Saltürk C; Çelik H
    Braz J Infect Dis; 2022; 26(1):102328. PubMed ID: 35139366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
    Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
    Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of hydroxychloroquine and favipiravir on clinical course in outpatients with COVID-19.
    Ömeroğlu ŞK; Temel F; Altun D; Öztop B
    Turk J Med Sci; 2021 Dec; 51(6):2827-2834. PubMed ID: 34165273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial.
    Dabbous HM; El-Sayed MH; El Assal G; Elghazaly H; Ebeid FFS; Sherief AF; Elgaafary M; Fawzy E; Hassany SM; Riad AR; TagelDin MA
    Sci Rep; 2021 Mar; 11(1):7282. PubMed ID: 33790308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir.
    Guner R; Hasanoglu I; Kayaaslan B; Aypak A; Akinci E; Bodur H; Eser F; Kaya Kalem A; Kucuksahin O; Ates I; Bastug A; Tezer Tekce Y; Bilgic Z; Gursoy FM; Akca HN; Izdes S; Erdem D; Asfuroglu E; Hezer H; Kilic H; Cıvak M; Aydogan S; Buzgan T
    J Infect Public Health; 2021 Mar; 14(3):365-370. PubMed ID: 33647553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity.
    Kaptein SJF; Jacobs S; Langendries L; Seldeslachts L; Ter Horst S; Liesenborghs L; Hens B; Vergote V; Heylen E; Barthelemy K; Maas E; De Keyzer C; Bervoets L; Rymenants J; Van Buyten T; Zhang X; Abdelnabi R; Pang J; Williams R; Thibaut HJ; Dallmeier K; Boudewijns R; Wouters J; Augustijns P; Verougstraete N; Cawthorne C; Breuer J; Solas C; Weynand B; Annaert P; Spriet I; Vande Velde G; Neyts J; Rocha-Pereira J; Delang L
    Proc Natl Acad Sci U S A; 2020 Oct; 117(43):26955-26965. PubMed ID: 33037151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of favipiravir on QTc interval in patients hospitalized with coronavirus disease 2019.
    Çap M; Bilge Ö; Işık F; Burak C; Karagöz A; İnci Ü; Akyüz A; Aslan B; Altıntaş B; Altındağ R; Kaya İ; Adıyaman MŞ; Süleymanoğlu M; Kaya Ş; Baysal E
    J Electrocardiol; 2020; 63():115-119. PubMed ID: 33181454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
    McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J
    Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nasopharyngeal SARS-CoV-2 Viral Load Response among COVID-19 Patients Receiving Favipiravir.
    Manosuthi W; Jeungsmarn S; Okada P; Suwanvattana P; Wongboot W; Thawornwan U; Charoenpong L; Wiboonchutikul S; Uttayamakul S; Pongpirul WA; Wachirapan A; Warachit P
    Jpn J Infect Dis; 2021 Sep; 74(5):416-420. PubMed ID: 33518623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU.
    Çalık Başaran N; Uyaroğlu OA; Telli Dizman G; Özışık L; Şahin TK; Taş Z; İnkaya AÇ; Karahan S; Alp Ş; Alp A; Metan G; Zarakol P; Sain Güven G; Öz ŞG; Topeli A; Uzun Ö; Akova M; Ünal S
    Turk J Med Sci; 2021 Apr; 51(2):411-420. PubMed ID: 32718127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease.
    AlQahtani M; Kumar N; Aljawder D; Abdulrahman A; Mohamed MW; Alnashaba F; Fayyad MA; Alshaikh F; Alsahaf F; Saeed S; Almahroos A; Abdulrahim Z; Otoom S; Atkin SL
    Sci Rep; 2022 Mar; 12(1):4925. PubMed ID: 35322077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.
    Solaymani-Dodaran M; Ghanei M; Bagheri M; Qazvini A; Vahedi E; Hassan Saadat S; Amin Setarehdan S; Ansarifar A; Biganeh H; Mohazzab A; Khalili D; Hosein Ghazale A; Reza Heidari M; Taheri A; Khoramdad M; Mahdi Asadi M; Nazemieh M; Varshochi M; Abbasian S; Bakhtiari A; Mosaed R; Hosseini-Shokouh SJ; Shahrokhi M; Yassin Z; Ali Zohal M; Qaraati M; Rastgoo N; Sami R; Javad Eslami M; Asghari A; Namazi M; Ziaie S; Jafari-Moghaddam R; Kalantari S; Memarian M; Khodadadi J; Hossein Afshari M; Momen-Heravi M; Behzadseresht N; Reza Mobayen A; Mozafari A; Movasaghi F; Haddadzadeh Shoushtari M; Moazen J
    Int Immunopharmacol; 2021 Jun; 95():107522. PubMed ID: 33735712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis.
    Manabe T; Kambayashi D; Akatsu H; Kudo K
    BMC Infect Dis; 2021 May; 21(1):489. PubMed ID: 34044777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia.
    Khamis F; Al Naabi H; Al Lawati A; Ambusaidi Z; Al Sharji M; Al Barwani U; Pandak N; Al Balushi Z; Al Bahrani M; Al Salmi I; Al-Zakwani I
    Int J Infect Dis; 2021 Jan; 102():538-543. PubMed ID: 33181328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EFFECTS OF HYDROXYCHLOROQUINE PLUS FAVIPIRAVIR TREATMENT ON THE CLINICAL COURSE AND BIOMARKERS IN HOSPITALIZED COVID-19 PATIENTS WITH PNEUMONIA.
    Delen LA; Gok A; Kasapoglu US; Cagasar O; Gok Z; Berber N; Derya S; Tetik B
    Acta Clin Croat; 2022 Nov; 61(3):403-411. PubMed ID: 37492367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.
    Hassanipour S; Arab-Zozani M; Amani B; Heidarzad F; Fathalipour M; Martinez-de-Hoyo R
    Sci Rep; 2021 May; 11(1):11022. PubMed ID: 34040117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial.
    Zhao H; Zhang C; Zhu Q; Chen X; Chen G; Sun W; Xiao Z; Du W; Yao J; Li G; Ji Y; Li N; Jiang Y; Wang Y; Zeng Q; Li W; Gong B; Chang X; Zhu F; Jiang X; Li J; Wu Z; Liu Y; Peng P; Wang G
    Int Immunopharmacol; 2021 Aug; 97():107702. PubMed ID: 33930706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
    Costanzo M; De Giglio MAR; Roviello GN
    Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial.
    Luvira V; Schilling WHK; Jittamala P; Watson JA; Boyd S; Siripoon T; Ngamprasertchai T; Almeida PJ; Ekkapongpisit M; Cruz C; Callery JJ; Singh S; Tuntipaiboontana R; Kruabkontho V; Ngernseng T; Tubprasert J; Abdad MY; Keayarsa S; Madmanee W; Aguiar RS; Santos FM; Hanboonkunupakarn P; Hanboonkunupakarn B; Poovorawan K; Imwong M; Taylor WRJ; Chotivanich V; Chotivanich K; Pukrittayakamee S; Dondorp AM; Day NPJ; Teixeira MM; Piyaphanee W; Phumratanaprapin W; White NJ;
    BMC Infect Dis; 2024 Jan; 24(1):89. PubMed ID: 38225598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.